

**SECTION I:
OVERVIEW and FEDERAL REGISTER DOCUMENTS**

A	Overview of the September 19 and 20, 2002 NDAC Meeting
B	Establishment of a Monograph for OTC Internal Analgesic, Antipyretic and Antirheumatic Products (Panel Report or ANPR) <i>[Entire Federal Register Notice Is Not Included]</i>
C	Internal Analgesic, Antipyretic and Antirheumatic Products for Over-The-Counter Human Use; Tentative Final Monograph <i>[Entire Federal Register Notice Is Not Included]</i>
D	Over-The-Counter Drug Products Containing Analgesic/Antipyretic Active Ingredients for Internal Use; Required Alcohol Warning (Notice of proposed rulemaking)
E.	Over-The-Counter Drug Products Containing Analgesic/Antipyretic Active Ingredients for Internal Use; Required Alcohol Warning (Final Rule)
F.	Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the - Counter Human Use; Final Rule for Professional Labeling of Aspirin, Buffered Aspirin, and Aspirin in Combination with Antacid Drug Products
G.	Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the - Counter Human Use; Proposed Amendment of the Tentative Final Monograph, and Related Labeling